Help us: Donate
Follow us on:



Sajad Zalzala on a Human Rapamycin Trial at EARD2020

This is a groundbreaking method of conducting human clinical trials.

Dr. Sajad Zalzala at Ending Age-Related Diseases 2020Dr. Sajad Zalzala at Ending Age-Related Diseases 2020

In this presentation given at Ending Age-Related Diseases 2020, Dr. Sajad Zalzala of AgelessRx discusses PEARL, a human trial of rapamycin that uses the participation of ordinary people in order to get a large sample size without the expense of a traditional clinical trial. He discusses the use and effectiveness of rapamycin as an aging treatment in previous studies of both rodents and people. He discusses the objectives of PEARL and provides reasons why this groundbreaking trial will not only provide evidence for the effectiveness of rapamycin in human beings but provide a new framework for future trials, aiding human longevity as a whole.

Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension: YouTube Facebook Twitter Instagram Instagram Discord
Thank You!


Related Community Members

  1. juancarbajal55714
    January 6, 2021

    I would like to join the Rapamycin trial

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.